Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94820
Title:
Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.
Authors:
Smyth, J F; Bowman, A; Perren, T; Wilkinson, Peter M; Prescott, R J; Quinn, K J; Tedeschi, M
Abstract:
BACKGROUND: Early clinical trials have suggested that glutathione (GSH) offers protection from the toxic effects of cisplatin. PATIENTS AND METHODS: One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH). The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity. RESULTS: When considering the proportion of patients receiving six courses of CDDP at any dose, GSH produced a significant advantage over control--58% versus 39%, (P = 0.04). For these patients there was a significant difference between the reduction in creatinine clearance for GSH treated patients compared with control--74% versus 62% (P = 0.006). Quality of life scores demonstrated that for patients receiving GSH there was a statistically significant improvement in depression, emesis, peripheral neurotoxicity, hair loss, shortness of breath and difficulty concentrating. As an indication of overall activity, these patients were statistically significantly more able to undertake housekeeping and shopping. Clinically assessed response to treatment demonstrated a trend towards a better outcome in the GSH group (73% versus 62%) but this was not statistically significant (P = 0.25). CONCLUSIONS: The results demonstrate that adding GSH to CDDP allows more cycles of CDDP treatment to be administered because less toxicity is observed and the patient's quality of life is improved.
Affiliation:
ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK.
Citation:
Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. 1997, 8 (6):569-73 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
Jun-1997
URI:
http://hdl.handle.net/10541/94820
PubMed ID:
9261526
Type:
Article
Language:
en
ISSN:
0923-7534
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSmyth, J Fen
dc.contributor.authorBowman, Aen
dc.contributor.authorPerren, Ten
dc.contributor.authorWilkinson, Peter Men
dc.contributor.authorPrescott, R Jen
dc.contributor.authorQuinn, K Jen
dc.contributor.authorTedeschi, Men
dc.date.accessioned2010-03-24T10:17:30Z-
dc.date.available2010-03-24T10:17:30Z-
dc.date.issued1997-06-
dc.identifier.citationGlutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. 1997, 8 (6):569-73 Ann. Oncol.en
dc.identifier.issn0923-7534-
dc.identifier.pmid9261526-
dc.identifier.urihttp://hdl.handle.net/10541/94820-
dc.description.abstractBACKGROUND: Early clinical trials have suggested that glutathione (GSH) offers protection from the toxic effects of cisplatin. PATIENTS AND METHODS: One hundred fifty-one patients with ovarian cancer (stage I-IV) were evaluated in a clinical trial of cisplatin (CDDP) +/- glutathione (GSH). The objective was to determine whether GSH would enhance the feasibility of giving six cycles of CDDP at 100 mg/m2 without dose reduction due to toxicity. RESULTS: When considering the proportion of patients receiving six courses of CDDP at any dose, GSH produced a significant advantage over control--58% versus 39%, (P = 0.04). For these patients there was a significant difference between the reduction in creatinine clearance for GSH treated patients compared with control--74% versus 62% (P = 0.006). Quality of life scores demonstrated that for patients receiving GSH there was a statistically significant improvement in depression, emesis, peripheral neurotoxicity, hair loss, shortness of breath and difficulty concentrating. As an indication of overall activity, these patients were statistically significantly more able to undertake housekeeping and shopping. Clinically assessed response to treatment demonstrated a trend towards a better outcome in the GSH group (73% versus 62%) but this was not statistically significant (P = 0.25). CONCLUSIONS: The results demonstrate that adding GSH to CDDP allows more cycles of CDDP treatment to be administered because less toxicity is observed and the patient's quality of life is improved.en
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntidotes-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCisplatin-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDouble-Blind Method-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshDrug Interactions-
dc.subject.meshFemale-
dc.subject.meshGlutathione-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshQuality of Life-
dc.titleGlutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.en
dc.typeArticleen
dc.contributor.departmentICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK.en
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.